In a significant development for rare disease research, Secretome Therapeuticsa Plano-based biotech company, has secured $30 million in funding to advance its work on treatments for Duchenne muscular dystrophy (DMD) and related heart conditions. This infusion of capital will support the company’s lead therapeutic candidate, STM-01and expand its research operations in North Texas.
DMD is a rare genetic disorder that causes progressive muscle weakness and degeneration. It primarily affects young males and is one of the most severe forms of muscular dystrophy. The disease often leads to heart complications, with cardiomyopathy being a leading cause of death among DMD patients.
Expanding Research and Operations
The recent funding, led by RA Capital Managementwill enable Secretome to advance its Phase 2 clinical trial for STM-01, a cell therapy designed to improve heart function in DMD patients. The company plans to relocate 10 to 15 scientists from its Chicago operations to BioLabs at Pegasus Park in Dallas, further strengthening its research capabilities in North Texas.
Vinny Jindalco-founder, president, and CEO of Secretome Therapeutics, expressed optimism about the company’s growth and the region’s emerging biotech hub. “I believe North Texas is steadily emerging as a more important life sciences and biotech hub,” Jindal said, “creating real opportunities for companies like Secretome to build here and recruit top talent from anywhere in the world.”
The Urgent Need for DMD Treatments
DMD affects approximately 15,000 people in the U.S. and more than 300,000 people worldwide. The disease is particularly devastating, with patients typically not living past their teenage years or early 20s. Current treatments, while helpful, have not significantly extended lifespan or addressed heart function effectively.
Secretome’s STM-01 aims to fill this critical gap. The therapy modulates inflammatory and fibrotic pathways to support myocardial function in DMD-related cardiomyopathy. Early Phase 1 data indicates that STM-01 improves physical and heart function and shows a favorable safety profile.
Navigating a Challenging Funding Landscape
The biotech funding landscape has been particularly challenging in recent years, with venture capital and private equity firms becoming more selective. Jindal described the past three years as a “nuclear winter for fundraising.” However, Secretome’s strategic pivot to individual investors and family offices kept the company afloat and its development programs moving forward.
The recent progress in the cell therapy space, including the first-ever FDA approval just 18 months ago, has renewed investor interest. This inflection point has paved the way for Secretome’s recent funding success. The company aims to broaden its clinical pipeline by introducing at least one more product into clinical studies to assess safety and efficacy.
With the new capital infusion, Secretome Therapeutics is poised to make significant strides in the fight against Duchenne muscular dystrophy. The company’s expansion in North Texas and its innovative approach to treating rare diseases offer hope to patients and their families worldwide.